Data as-of 2026-07-06 close.

The managed-care/pharma re-rate that was "fully priced" 10 sessions ago cooled off cleanly — UNH, CVS, JNJ, MRK, BIIB all dropped 8-14 RSI points while mostly holding or slightly giving back price, exactly the digestion the last scan called for. The new extreme names are VRTX (RSI 81.6, near ATH) and MRNA (RSI 81.9, +114.7% vs VWAP), both of which broke out hard from the "hold, extended" tier. VEEV also reversed out of "avoid" territory with a genuine +12% run. ISRG continues its recovery; PFE remains the lone deep-oversold watch. AMGN is still the cleanest large-cap accumulate, two scans running.

Source: healthcare-scan.json. Latest bar 2026-07-06. Prior scan: 2026-06-26-healthcare-scan (watchlist swapped ZTS out for GRDN since then).

‡GH (Guardant Health) appears in the raw healthcare.json universe alongside GRDN but is not part of the curated healthcare-scan.json watchlist; included here as a notable adjacent name since it shares GRDN's liquid-biopsy/diagnostics space.

• PFE ($23.72, RSI 35) — Pfizer: down GC, -4.1% vs VWAP, -17.5% from ATH, -7.4% 30D. Still the lone genuinely oversold name in the scan — unchanged conclusion from last scan. GC intact but hasn't turned into a bounce yet.
• SYK ($324.73, RSI 57) — Stryker: weak-up DC, -6.05% vs VWAP, cooling off a small bounce (-1.8% this week).
• GRDN ($41.38, RSI 53) — Guardant Health: new to this watchlist iteration (replaced ZTS). strong-up GC, +27.3% vs VWAP, flat this week. Needs a scan or two of history before drawing conclusions.
• GILD, DXCM — Unremarkable, steady, not extended.

This is the biggest structural shift since the last scan: BIIB (69.3→56.2), MRK (70.8→60.2), CVS (71.8→59.0), UNH (72.6→59.4) all dropped 8-14 RSI points while giving back little to no price (UNH and CVS are both still up 3-5% over the 10 sessions). This is the "hold, don't chase, wait for the extension to resolve" call from the last scan playing out cleanly via time, not price decline. AMGN and TMO remain the two cleanest accumulate setups — AMGN never got extended in the first place, and TMO just posted its best 7D print (+3.9%) in two scans while approaching an SMA200 reclaim.

• ISRG ($432.83, RSI 60) — Continuing its multi-scan recovery (was RSI 41.6 two scans ago); still weak-up DC and -10.24% vs VWAP, thesis: intact.
• MDT, ABT — Both still below SMA200 in weak-up DC regimes; relief bounces, not reclaims.

• JNJ ($259.33, RSI 68) — Cooled from 72.4; still near ATH (-1.4%) but the RSI compression is the story here.
• VEEV ($192.01, RSI 69) — The scan's clearest reversal. Two scans ago this was RSI 57 and flagged "avoid" on a -20.4% SMA200 gap. It's now +14.6% above SMA20 with a genuine +8.8% weekly move — still weak-up DC (hasn't confirmed a trend flip) but the price action is a real turn, not noise.
• LLY, IQV — Both extended but not accelerating; hold, don't add.

• VRTX ($529.59, RSI 82) — Jumped from a stale RSI 69.2 read last scan to 81.6 on a genuine +10.3% move. Near ATH, strong-up GC. This is a new extreme, not a continuation of an old one.
• MRNA ($81.80, RSI 82) — The sector's (and the entire cross-scan dataset's) most extreme name: +71.9% in 30 days, +114.7% above VWAP, up from +82% vs VWAP last scan. Hold if owned from lower levels; do not initiate.

• The managed-care/pharma cooldown is the headline. BIIB (69.3→56.2), MRK (70.8→60.2), CVS (71.8→59.0), UNH (72.6→59.4), JNJ (72.4→68.0), LLY (72.7→64.0) all dropped meaningfully in RSI while mostly holding or gaining price. This is exactly the "resting, not correcting" pattern the desk should expect from a fully-priced sector — validates last scan's "hold, don't chase" calls across the board.
• VRTX and MRNA are the sector's new extremes. VRTX jumped from a stale RSI 69.2 to a genuine 81.6 on +10.3% price. MRNA deepened from RSI 71.4/+82% VWAP to RSI 81.9/+114.7% VWAP — a +21.6% price move in 10 sessions. These replace UNH/CVS/JNJ/MRK as the names to flag "don't chase."
• VEEV reversed out of the "avoid" tier. RSI 57.0→69.4, price +14.8% over 10 sessions, +8.8% in the last week alone. Genuine turn, still needs a trend confirmation (still weak-up DC).
• ISRG continued its multi-scan recovery (RSI 41.6→59.9, +7.0% price) — consistent with the same pattern seen in the biotech-scan cut of this name.
• PFE remains unchanged and unresolved — still the lone deep-oversold name at RSI 34.6 (was 36.2), still no bounce signal.
• Watchlist composition changed: ZTS (which was collapse regime, -53% from ATH last scan) was replaced by GRDN in the healthcare-scan.json universe. No like-for-like comparison possible for GRDN yet.

• VRTX/MRNA at RSI 82: what catalyst, if any, justifies holding through a mean-reversion risk this extreme?
• VEEV: does the reversal confirm with a golden cross next scan, or was this a single-week bounce in a still-broken healthcare-SaaS name?
• GRDN: no prior baseline — is RSI 53 basing or drifting? Needs at least one more scan to classify.